Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513650 | 1.00 | ADORA3 (0.65) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12031327 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL25937 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL2550330 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL23050294 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL24538798 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL25936 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12150808 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL21344303 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1DPP4MEN1SLC28A1 | |
| SCHEMBL12746919 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210189392-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RIBOZYME PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6586238-B1 | Modified ribozymes; useful for cleavage of RNA or single-stranded DNA; Resistance to exonuclease degradation | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RNGTT, MTAP, RNASEL | ADORA3 2216/4885ADORA1 3137/4885DPP4 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.